Resumen: Illumina colabora con 54gene en la creación de un centro de genómica de clase mundial en Nigeria

CAMBRIDGE, Inglaterra–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) ha anunciado hoy una colaboración con 54gene, una empresa de tecnología sanitaria cuya misión es hacer avanzar las capacidades de la medicina de precisión en África a través de la investigación, los diagnósticos moleculares avanzados y los programas clínicos. La asociación ayudará a la creación de una nueva instalación... Read more

Illumina arbeitet mit 54gene bei der Schaffung einer Genomik-Einrichtung von Weltklasse in Nigeria zusammen

CAMBRIDGE, England–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) gab heute eine Zusammenarbeit mit 54gene bekannt, einem Unternehmen der Gesundheitstechnologie, dessen Aufgabe es ist, die Fähigkeiten der Präzisionsmedizin in Afrika durch Forschung, fortschrittliche molekulare Diagnostik und klinische Programme zu fördern. Die Partnerschaft wird die Einrichtung einer neuen Genetik-Einrichtung in Lagos, Nigeria, unterstützen, die mit einer Reihe von Illuminas... Read more

Riassunto: Illumina collabora con 54gene alla creazione di un centro di genomica di eccellenza in Nigeria

CAMBRIDGE, Inghilterra–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) ha annunciato oggi una collaborazione con 54gene, società operante nel campo delle tecnologie sanitarie la cui missione è promuovere le competenze della medicina di precisione in Africa attraverso ricerca, diagnostica molecolare avanzata e programmi clinici. La partnership sosterrà la creazione di un nuovo centro di genetica a Lagos, in... Read more

Samenvatting: Illumina werkt samen met 54gene bij de oprichting van een genomics-faciliteit van wereldklasse in Nigeria

CAMBRIDGE, Engeland–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) kondigde vandaag een samenwerking aan met 54gene, een gezondheidstechnologiebedrijf dat tot doel heeft de capaciteiten van precisiegeneeskunde in Afrika te vergroten door middel van onderzoek, geavanceerde moleculaire diagnostiek en klinische programma’s. Het partnerschap ondersteunt de oprichting van een nieuwe genetica-faciliteit in Lagos, Nigeria, uitgerust met een reeks van Illumina’s... Read more

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status Affordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of... Read more

Health Canada Licenses First Artificial Intelligence Algorithms Embedded On-Device to Prioritize Critical Chest X-ray Review

Critical Care Suite helps radiologists prioritize critical cases with a suspected pneumothorax – a type of collapsed lung – by immediately flagging critical cases to radiologists for triage, which could drastically cut the average review time from up to eight hours[1] Offers first-of-its-kind automated AI quality check features that detect acquisition errors, flagging images for... Read more

| CDX Installation Profile

| CDX Installation Profile Skip to main content Drupal already installed To start over, you must empty your existing database and copy default.settings.php over settings.php. To upgrade an existing installation, proceed to the update script. View your existing site. http://www.genewsroom.com/feeds/healthcare.rss.xml Read more

Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S. Under this collaboration, the overall capacity of REGN-COV2 is expected to... Read more

【Delayed】Announcement on revision of financial forecast

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese... Read more